H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Get your full text copy in PDF

Improvement of Survival Rate for Patients with Hepatocellular Carcinoma Using Transarterial Chemoembolization in Combination with Three-Dimensional Conformal Radiation Therapy: A Meta-Analysis

Houqiao Bai, Peng Gao, Hao Gao, Guangxi Sun, Chonghai Dong, Jian Han, Guosheng Jiang

(Department of Internal Medicine, Maternity and Child Care, Weihai, Shandong, China (mainland))

Med Sci Monit 2016; 22:1773-1781

DOI: 10.12659/MSM.895548


BACKGROUND: Transarterial chemoembolization (TACE) has been used alone or in combination with three-dimensional conformal radiation therapy (3DCRT) for treating hepatocellular carcinoma (HCC). The overall survival rate of HCC patients undergoing both treatments, however, has not been systematically studied. The aim of this meta-analysis-based study was to evaluate the overall efficacy of the combined therapy or monotherapy, thereby providing information for clinical treatment.
MATERIAL AND METHODS: We searched Google Scholar, PubMed, and Chinese National Knowledge Infrastructure (CNKI) for eligible studies, and a total of 17 case-control studies (including HCC patients treated by TACE plus 3DCRT or TACE alone) were included to perform the meta-analysis. Based on the available data, we assessed the improvements of 1-year, 2-year, and 3-year survival rate for the combination therapy of TACE and 3DCRT or TACE alone. Furthermore, the analysis was also stratified by the tumor response: complete response (CR), partial response (PR), no response (NR) and progressive disease (PD). Statistical analysis was performed using STATA 12 (Stata Statistical Software: Release 12).
RESULTS: The results show that HCC patients receiving combination therapy have significantly increased overall survival rate when compared to those receiving TACE alone (1-year survival rate: OR=1.95, 95% CI 1.54–2.47, p=7.3×10^–8; 2-year survival rate: OR=1.87, 95% CI 1.49–2.34, p=1.6×10^–7; 3-year survival rate: OR=2.00, 95% CI 1.52–2.64, p=1.8×10^–6).
CONCLUSIONS: Assessment of tumor response demonstrates that the combination therapy can efficiently increase the tumor response rate (CR+PR: OR=2.29, 95% CI 1.70–3.08, p=1.1×10^–7), with a lower rate of subsequent tumor development (PD: OR=0.25, 95% CI 0.15–0.40, p=5.5×10^–8).

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree